EUVIMEDScopri EUVIMED
Open access · CC BY-NC-ND 4.0

Evaluation of oral telmisartan administration as a suppression test for diagnosis of primary hyperaldosteronism in cats

Virginie Fabrès, Renaud Dumont iD, Mélanie Garcia, Dan Rosenberg, Benoit Rannou, Maxine Kurtz iD, Ghita Benchekroun iD

Journal of Veterinary Internal Medicine · 2023

DOI: 10.1111/jvim.16689 ↗

At a glance

Journal article in Journal of Veterinary Internal Medicine, 2023. Written by Virginie Fabrès and 6 co-authors. Institution: Ecole Nationale Veterinaire d'Alfort, CHUVA, Service de médecine interne, Maisons-Alfort, Île-de-France, F-94700, France. Major MEDLINE topics: Cat Diseases, Hyperaldosteronism, Hypertension. Cited 7 times so far (Crossref); 15 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background

Development of a telmisartan-based suppression test may facilitate the diagnosis of primary hyperaldosteronism (PHA) in cats, which remains difficult today.

Objectives

To develop a telmisartan suppression test (TST) that is safe, and able to suppress aldosterone secretion in healthy cats but not in cats with PHA. Animals Ten healthy cats and 6 cats with PHA.

Methods

Prospective study using a placebo-controlled crossover design to investigate a TST in healthy cats, and evaluation of TST in cats with PHA. Plasma aldosterone concentration, potassium concentration, and systolic blood pressure (SBP) were measured before (T0), and 1 hour (T1) and 1.5 hours after (T1.5) PO administration of 1 mg/kg of telmisartan, 2 mg/kg of telmisartan or placebo.

Results

Median age in healthy cats was 3 years old (range, 1-7). In healthy cats, a telmisartan dose of 2 mg/kg significantly decreased aldosterone concentration at T1 and T1.5 compared with T0. Placebo had no significant effect on aldosterone concentration. In cats diagnosed with PHA, a 2-mg/kg dose of telmisartan did not induce any significant change in aldosterone concentration at T1 or T1.5 compared with T0. No adverse effects of telmisartan (e.g., hyperkalemia, systemic hypotension) were observed in any cats. Conclusions and Clinical Importance The oral TST shows promise as a diagnostic test for the diagnosis of PHA in cats.

Subjects

MeSH terms (MEDLINE)

Cat DiseasesHyperaldosteronismHypertensionAnimalsCatsAldosteroneBlood PressureProspective StudiesTelmisartan

Author keywords

Conn diseaseadrenal disordercardiologycardiovascularfelinehemodynamicshypertensionhypokalemia

Substances

AldosteroneTelmisartan

Authors and institutions

  • Ecole Nationale Veterinaire d'Alfort, CHUVA, Service de médecine interne, Maisons-Alfort, Île-de-France, F-94700, France.
  • Centre Hospitalier Vétérinaire Aquivet, Service de médecine interne, F-33320, Eysines (Bordeaux), France.
  • Centre Hospitalier Veterinaire Frégis, Service de médecine interne, 43 avenue Aristide Briand, Arcueil, 94110, France.
  • Micen Vet, Service de médecine interne, Créteil, France.
  • VetAgro Sup, Service de Pathologie clinique, Marcy-l'Etoile, Auvergne-Rhône-Alpes, France.
  • AzurVet-Lab, Laboratoire de biologie médicale, St-Laurent-du-Var, France.

ORCID profiles: Renaud Dumont, Maxine Kurtz, Ghita Benchekroun

Cite

APA

Fabrès, V., Dumont, R., Garcia, M., Rosenberg, D., Rannou, B., Kurtz, M., & Benchekroun, G. (2023). Evaluation of oral telmisartan administration as a suppression test for diagnosis of primary hyperaldosteronism in cats. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.16689

Vancouver

Fabrès V, Dumont R, Garcia M, Rosenberg D, Rannou B, Kurtz M, et al. Evaluation of oral telmisartan administration as a suppression test for diagnosis of primary hyperaldosteronism in cats. Journal of Veterinary Internal Medicine. 2023. doi:10.1111/jvim.16689

BibTeX
@article{Fabrs2023,
  author = {Fabrès, Virginie and Dumont, Renaud and Garcia, Mélanie and Rosenberg, Dan and Rannou, Benoit and Kurtz, Maxine and Benchekroun, Ghita},
  title = {Evaluation of oral telmisartan administration as a suppression test for diagnosis of primary hyperaldosteronism in cats},
  journal = {Journal of Veterinary Internal Medicine},
  year = {2023},
  doi = {10.1111/jvim.16689}
}
Start for free →